VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHOC 2022 | Novel investigational drugs and promising therapies for immune thrombocytopenia

Drew Provan, BSc, MBChB, MD, FRCP, FRCPath, Queen Mary University of London, London, UK, gives an overview of novel agents being explored for the treatment of immune thrombocytopenia (ITP), including thrombopoietin (TPO) receptor agonists, Bruton’s tyrosine kinase (BTK) inhibitors, and complement inhibitors. This interview took place at the XIII Eurasian Hematology-Oncology Congress (EHOC) held in Istanbul, Turkey.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Research support: Amgen, Novartis
Honoraria: Amgen, Novartis, SOBI, UCB, argenx
Consultancies: UCB, MedImmune, Ono, SOBI, argenx

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter